Co-Investigator 
Dr.Ticehurst is a virologist member of The Johns Hopkins Applied Physics Laboratory (JHU-APL) Senior Professional Staff and is a part-time Assistant Professor at The Johns Hopkins Hospital's (JHH) Medical Microbiology Division and School of Medicine (SOM). In addition to years of experience as a faculty member, virologist and clinical microbiologist, he has developed new diagnostic assays, authored protocols for test performance. He will be involved in developing key questions for the focus groups and in needs assessment survey design. He is certified in Clinical Pathology. He was the Clinical Laboratories Director JH-Bayview Medical Center (2001-2007), and has previous pertinent experience as a Food and Drug Administration (FDA) Medical Officer, clinical laboratorian, and developer of clinical and research assays.
During 1995-2001, he was part of FDA's group that evaluates most clinical laboratory assays for US approval or clearance. He was a Medical Officer for this group's Microbiology Branch. He was primary author of a CDRH guidance document on HCV assays and lead reviewer for the first FDA-approved HCV RNA assays to be FDA approved (Roche Amplicor and Cobas Amplicor HCV Tests v 2.0: 2001). He has been a consultant for ViroPharma, evaluating its "real time" PCR assay for picornaviruses. Dr. Ticehurst has been on faculty of JHH Medical Microbiology Division since 1995, for which he led development of its first PCR-based assay for enteroviruses. He co-authored the 2003 NCCLS guideline, Quantitative molecular methods for infectious diseases, and was an invited contributor to CDC efforts on HCV testing (1998) and rapid testing for syphilis and hepatitis viruses (2001).
For Core 1, Dr. Ticehurst will serve as a resource for obtaining clinical specimens for the Core 1 laboratory, as well as providing access to POC clinics, that can test the performance of existing and new POCT. His expertise as an MD, FDA scientist, and laboratorian will be valuable in helping accelerate and integrate adoption of POCT into systems for clinical use, and transitioning prototype devices into clinical research networks for later-stage testing.
